You are here

  • Home
  • Archive
  • Volume 69, Issue 2
  • Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects

Citation Tools

Article menu
Download PDFPDF
PostScript
Letter
Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
von Cube MK, Schumacher M, Wolkewitz M on behalf of COMBACTE-MAGNET Consortium
Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects
Gut 2020;69:398-400.